TY - JOUR
T1 - The prognostic impact of circulating miRNAs in patients with advanced esophagogastric cancer during palliative chemotherapy
AU - van Zweeden, Annette A
AU - Opperman, Roza C M
AU - Honeywell, Richard J
AU - Peters, Godefridus J
AU - Verheul, Henk M W
AU - van der Vliet, Hans J
AU - Poel, Dennis
N1 - Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
PY - 2021
Y1 - 2021
N2 - The prognosis of patients with advanced oesophageal cancer (EC) and gastric cancer (GC) is poor. Circulating microRNAs (ci-miRNAs) may have prognostic and predictive value to improve patient selection for palliative treatment. The purpose of this study is to assess the prognostic and predictive value of specific ci-miRNAs in plasma of patients with EC and GC treated with first-line palliative gemcitabine and cisplatin. Droplet digital PCR (ddPCR) was used to quantify miR-200c-3p, miR-375, miR-21-5p, miR-148a-3p, miR-146a-5p, miR-141-3p and miR-218-5p in plasma from 68 patients. ci-miRNA expression was analyzed in relation to overall survival (OS), progression-free survival (PFS), and response to chemotherapy. ci-miRNA levels were detectable in 36 baseline (71%) samples and in 14 (47%) follow-up samples. Increased circulating miR-200c-3p in GC showed a trend (p = 0.06) towards a shorter OS. High circulating miR-375 was associated with a longer OS (p = 0.02) in patients with esophageal adenocarcinoma (EAC). No significant difference was observed in ci-miRNA expression between paired pre- and on-treatment samples. ci-miRNA expression was not associated with response to chemotherapy. ci-miRNAs can be measured in plasma samples of patients treated with first-line palliative chemotherapy using ddPCR despite prolonged storage in heparin. Elevated circulating miR-375 might be a prognostic marker for patients with EAC.
AB - The prognosis of patients with advanced oesophageal cancer (EC) and gastric cancer (GC) is poor. Circulating microRNAs (ci-miRNAs) may have prognostic and predictive value to improve patient selection for palliative treatment. The purpose of this study is to assess the prognostic and predictive value of specific ci-miRNAs in plasma of patients with EC and GC treated with first-line palliative gemcitabine and cisplatin. Droplet digital PCR (ddPCR) was used to quantify miR-200c-3p, miR-375, miR-21-5p, miR-148a-3p, miR-146a-5p, miR-141-3p and miR-218-5p in plasma from 68 patients. ci-miRNA expression was analyzed in relation to overall survival (OS), progression-free survival (PFS), and response to chemotherapy. ci-miRNA levels were detectable in 36 baseline (71%) samples and in 14 (47%) follow-up samples. Increased circulating miR-200c-3p in GC showed a trend (p = 0.06) towards a shorter OS. High circulating miR-375 was associated with a longer OS (p = 0.02) in patients with esophageal adenocarcinoma (EAC). No significant difference was observed in ci-miRNA expression between paired pre- and on-treatment samples. ci-miRNA expression was not associated with response to chemotherapy. ci-miRNAs can be measured in plasma samples of patients treated with first-line palliative chemotherapy using ddPCR despite prolonged storage in heparin. Elevated circulating miR-375 might be a prognostic marker for patients with EAC.
KW - Aged
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Cisplatin/administration & dosage
KW - Clinical Trials, Phase II as Topic
KW - Deoxycytidine/administration & dosage
KW - Esophageal Neoplasms/blood
KW - Esophagogastric Junction
KW - Female
KW - Folic Acid/administration & dosage
KW - Humans
KW - Male
KW - MicroRNAs/blood
KW - Middle Aged
KW - Palliative Care
KW - Prognosis
KW - Progression-Free Survival
KW - Randomized Controlled Trials as Topic
KW - Stomach Neoplasms/blood
KW - Survival Rate
UR - http://www.scopus.com/inward/record.url?scp=85104060719&partnerID=8YFLogxK
U2 - 10.1016/j.ctarc.2021.100371
DO - 10.1016/j.ctarc.2021.100371
M3 - Article
C2 - 33866108
SN - 2468-2942
VL - 27
JO - Cancer Treatment and Research Communications
JF - Cancer Treatment and Research Communications
M1 - 100371
ER -